Adzenys Xr-odt Tablet, Orally Disintegrating
Product Images NDC 70165-030

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Adzenys Xr-odt (NDC 70165-030). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Neos Therapeutics Brands, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Adzenys Xr Odt 1

FDA Label Image

Adzenys Xr Odt 2

Adzenys Xr Odt 2
This appears to be a chart showing the mean concentration (in ng/mL) of different types of amphetamines (Dextroamphetamine and Levoamphetamine) at different time intervals (in hours), as well as their respective extended release forms (Amphetamine XR-ODT and MAS ER).*
FDA Label Image

Adzenys Xr Odt 3

Adzenys Xr Odt 3
Adzenys XR-ODT is a medication that comes in the form of orally disintegrating tablets containing 3.1 mg of amphetamine per tablet. This medication is packaged in a container that includes 30 tablets (on 5 blister cards) and a travel case. The pharmacist should dispense the enclosed medication guide with each patient. The barcode NDC for this medication is 70165-005-30. The remaining text is not legible.*
FDA Label Image

Adzenys Xr Odt 4

Adzenys Xr Odt 4
This is a medication called Adzenys XR-ODT in the form of extended-release orally disintegrating tablets that contains 6.3 mg of amphetamine (equivalent to that in a 10 mg strength mixed salts of a single-entity amphetamine product). The medication guide should be dispensed to each patient for proper and safe use. It comes in a travel case along with 30 tables (5 x Scount blstr cad) and pharmacist's instructions. NDC code of the medicine is 70165-010-30 and it is Rx only.*
FDA Label Image

Adzenys Xr Odt 5

Adzenys Xr Odt 5
This is a description of a medication called Adzenys XR-ODT™. It is an orally disintegrating tablet that should not be crushed or chewed. This medication contains 9.4 mg of amphetamine which is equal to a 15 mg strength mixed salts of a single-entity amphetamine product. The package has a Medication Guide enclosed and is intended for dispensation by a pharmacist to a patient. The rest of the text appears to be illegible or not relevant to the description.*
FDA Label Image

Adzenys Xr Odt 6

Adzenys Xr Odt 6
Adzenys XR-ODT is a medication that comes in a package containing 30 orally disintegrating tablets of 125mg of amphetamine (equivalent to 20 mg mixed salts of a single-entity amphetamine product). The package includes five blister cards with six tablets each and a travel case. The medication guide enclosed in the package needs to be given to each patient. The drug should not be chewed or crushed. The product's NDC number is 70165-020-30. Dosage should be individualized and should be taken with caution. The rest of the text is not readable.*
FDA Label Image

Adzenys Xr Odt 7

Adzenys Xr Odt 7
This is a description of Adzenys XR-ODT, a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD). It comes in tablet form and contains 15.7 mg of amphetamine. It is an extended-release medication that dissolves quickly in the mouth and should not be chewed or crushed. The package contains 30 tablets and a medication guide for patients. The National Drug Code (NDC) for Adzenys XR-ODT is 7016502530.*
FDA Label Image

Adzenys Xr Odt 8

Adzenys Xr Odt 8
This is a medication called Adzenys XR-ODT, which comes in the form of orally disintegrating tablets to treat ADHD. Each tablet contains 188mg of amphetamine, equivalent to a 30 mg strength mixed salts 18.8mg, and it comes in a travel case with 30 tablets. Pharmacists should dispense an enclosed medication guide to each patient. The package includes NDC 70165-030-30 and Rx Only labels.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.